Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback